carnitine has been researched along with Heart Valve Diseases in 5 studies
Heart Valve Diseases: Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the tissue carnitine level in patients with chronic heart failure, we obtained biopsy specimens of the left ventricular papillary muscle from 8 patients with mitral valve disease undergoing valve replacement surgery." | 7.68 | Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. ( Kobayashi, A; Masumura, Y; Yamazaki, N, 1990) |
| "Reduced myocardial carnitine concentrations in the explanted heart and elevated plasma levels have been found in patients undergoing heart transplant for end-stage congestive heart failure (CHF)." | 7.68 | Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. ( Fleck, E; Regitz, V; Shug, AL, 1990) |
| "To study the tissue carnitine level in patients with chronic heart failure, we obtained biopsy specimens of the left ventricular papillary muscle from 8 patients with mitral valve disease undergoing valve replacement surgery." | 3.68 | Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure. ( Kobayashi, A; Masumura, Y; Yamazaki, N, 1990) |
| "Reduced myocardial carnitine concentrations in the explanted heart and elevated plasma levels have been found in patients undergoing heart transplant for end-stage congestive heart failure (CHF)." | 3.68 | Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases. ( Fleck, E; Regitz, V; Shug, AL, 1990) |
| "L-carnitine was added to the crystalloid cardioplegic solution for experimental group 1 (3 g/L) and experimental group 2 (6 g/L), whereas no L-carnitine was used in the control group." | 2.82 | Myocardial Protective Effects of L-Carnitine on Ischemia-Reperfusion Injury in Patients With Rheumatic Valvular Heart Disease Undergoing Cardiac Surgery. ( Li, M; Sun, H; Xu, S; Xue, L, 2016) |
| "L-carnitine was added to the crystalloid cardioplegic solution for experimental group 1 (6 g/L) and experimental group 2 (12 g/L), whereas no L-carnitine was used in the control group." | 1.51 | The protective effects of L-carnitine on myocardial ischaemia-reperfusion injury in patients with rheumatic valvular heart disease undergoing CPB surgery are associated with the suppression of NF-κB pathway and the activation of Nrf2 pathway. ( Deng, C; Geng, Y; Hao, J; Li, M; Li, W; Li, Y; Sun, L; Wang, H; Wang, R; Xu, S; Xue, L; Yan, Y; Yi, Q; Zhang, Y, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 2 |
| Xu, S | 2 |
| Geng, Y | 1 |
| Sun, L | 1 |
| Wang, R | 1 |
| Yan, Y | 1 |
| Wang, H | 1 |
| Li, Y | 1 |
| Yi, Q | 1 |
| Zhang, Y | 1 |
| Hao, J | 1 |
| Deng, C | 1 |
| Li, W | 1 |
| Xue, L | 2 |
| Sun, H | 1 |
| Nakagawa, T | 1 |
| Sunamori, M | 1 |
| Suzuki, A | 1 |
| Masumura, Y | 1 |
| Kobayashi, A | 1 |
| Yamazaki, N | 1 |
| Regitz, V | 1 |
| Shug, AL | 1 |
| Fleck, E | 1 |
1 trial available for carnitine and Heart Valve Diseases
| Article | Year |
|---|---|
Myocardial Protective Effects of L-Carnitine on Ischemia-Reperfusion Injury in Patients With Rheumatic Valvular Heart Disease Undergoing Cardiac Surgery.
Topics: Adult; Apoptosis; bcl-2-Associated X Protein; Biomarkers; Cardioplegic Solutions; Cardiopulmonary By | 2016 |
4 other studies available for carnitine and Heart Valve Diseases
| Article | Year |
|---|---|
The protective effects of L-carnitine on myocardial ischaemia-reperfusion injury in patients with rheumatic valvular heart disease undergoing CPB surgery are associated with the suppression of NF-κB pathway and the activation of Nrf2 pathway.
Topics: Biomarkers; Carnitine; Female; Heart Valve Diseases; Humans; Male; Middle Aged; Myocardial Reperfusi | 2019 |
The myocardial distribution and plasma concentration of carnitine in patients with mitral valve disease.
Topics: Carnitine; Female; Heart Valve Diseases; Heart Ventricles; Humans; Male; Mitral Valve; Myocardium; P | 1994 |
Myocardial free carnitine and fatty acylcarnitine levels in patients with chronic heart failure.
Topics: Adult; Aged; Animals; Autopsy; Biopsy; Carnitine; Chronic Disease; Dogs; Female; Heart Failure; Hear | 1990 |
Defective myocardial carnitine metabolism in congestive heart failure secondary to dilated cardiomyopathy and to coronary, hypertensive and valvular heart diseases.
Topics: Adult; Biopsy; Cardiomyopathy, Dilated; Carnitine; Coronary Disease; Endocardium; Energy Metabolism; | 1990 |